The topic of intellectual property rights protection in the pharmaceutical industry was discussed at SPIEF 2026
15.06.2026
Corporate
For investors
15.06.2026
June 15 2026, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly and hereinafter – "PROMOMED", the "Company", and together with its subsidiaries, the "Group") informs that the Rating Agency Expert RA (hereinafter referred to as Expert RA, the Agency) has upgraded the credit rating of the subsidiary PROMOMED LLCDM"up to the level of "ruA". The rating outlook is stable.
The credit rating upgrade is due to an increase in the scale of operations as a result of the introduction of high-margin innovative drugs to the market, which led to an improvement in debt metrics against the background of faster EBITDA growth and a stronger liquid position, which was also facilitated by the use of diversified business funding channels.
The Agency also expects further growth in operating performance in the medium term and maintaining high profitability while maintaining a comfortable debt burden without increasing debt.
The RA expert emphasizes the resilience of the pharmaceutical market to external shocks in conditions of high social importance, stimulating the growth of clinical trials and localization of foreign drugs. At the same time, the need for significant capital investments in production facilities, R&D and clinical research create barriers to entry for new players, while the market itself is growing at a double-digit pace.
The rating agency's press release is published on the website: https://raexpert.ru /.
The upgrade of the Expert RA rating was the second rating action in 2026. Earlier, the NRA agency assigned a credit rating to PROMOMED DM LLC at the "A|ru|" level (rating action dated February 16, 2026). In addition, in January 2026, the NRA assigned a five-star rating to PROMOMED shares at the highest level with a growth potential of up to 773 rubles per share.
"The next increase in the rating of PROMOMED Group is a natural result of the successful implementation of our long—term development strategy and the company's work in 2025-2026.
Today, PROMOMED's status as a high-quality and reliable borrower with attractive business prospects has been confirmed by two independent market experts."About the Company
PROMOMED is a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market.
The company's structure includes its own unique world-class R&D center and a high—tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company is developing a diversified portfolio of more than 360 medicines in the top 10 segments of the pharmaceutical market. The company's portfolio includes blockbuster drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the company produces drugs for the treatment of diseases in various therapeutic areas: endocrinology, oncology, neurology, autoimmune diseases, infection control, acute and chronic pain, and others. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the company is an active participant in the system of ensuring national drug safety and import independence of the country.
Contacts
|
For investors |
For the media |
Statement of Limitation of liability
This message and the information contained therein are not:
● an offer to purchase any securities,
● an invitation to make offers to purchase any securities,
● as part of such an offer or invitation,
● securities advertising in the Russian Federation or other jurisdictions,
● an offer to purchase medicines,
● advertising of medicines,
● by encouraging or recommending transactions,
● and is also not subject to interpretation as such.
Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.
Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.
The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.
Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page https://e-disclosure.ru/portal/company.aspx?id=38533.
The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.
The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any
guarantees or representations confirming the accuracy, completeness or unambiguous nature of the information and information contained in this message or related materials, and do not assume any obligations or obligations to update them.
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
